Early bladder cancer: Concept, diagnosis, and management

被引：31

作者：

Kitamura H. ^{[1
]}

Tsukamoto T. ^{[1
]}

机构：

[1] Department of Urology, Sapporo Medical University, School of Medicine, Chuo-ku, Sapporo 060-8543

来源：

International Journal of Clinical Oncology | 2006年 / 11卷 / 1期

关键词：

Bladder; Cancer; Progression; Recurrence; Treatment; Urine markers;

D O I：

10.1007/s10147-006-0552-y

中图分类号：

学科分类号：

摘要：

Recent evidence on molecular pathways helps us to understand the pathogenesis of bladder cancer. However, the molecular mechanisms of recurrence of the disease and progression into muscle-invasive disease are not fully understood. The diagnostic accuracy and specificity of innovative markers for detection of the disease currently available in the clinical setting are still far from the level where cystoscopy would not be needed. Although risk factors for progression to muscle-invasive disease have been identified, we still cannot predict accurately the clinical behavior of superficial bladder cancer. In this review article, we summarize recent evidence on molecular pathogenesis, risk factors for recurrence and progression, urine markers for detection, and treatments in superficial bladder cancer. © The Japan Society of Clinical Oncology 2006.

引用

页码：28 / 37

页数：9

共 96 条

[1]

Witje J.A., Debruyne F.M.J., Vogelzang N.J., Scardino P.T., Shipley W.U., Et al., Natural history and initial management based on prognostic factor, Comprehensive Textbook of Genitourinary Oncology 3rd Edn., pp. 449-451, (2005)

[2]

Tsukamoto T., Kitamura H., Takahashi A., Masumori N., Treatment of invasive bladder cancer. Lessons from the past and perspective for the future, Jpn J Clin Oncol, 34, pp. 295-306, (2004)

[3]

Epstein J.I., Amin M.B., Reuter V.E., Mostofi F.K., The World Health Organization/International Society of Urological Pathology consensus classification of urothelial neoplasms of the urinary bladder, Am J Surg Pathol, 22, pp. 1435-1448, (1998)

[4]

Donat S.M., Evaluation and follow-up strategies for superficial bladder cancer, Urol Clin N Am, 30, pp. 765-776, (2003)

[5]

Holmang S., Follow-up of patients with noninvasive and superficially invasive bladder cancer, Semin Urol Oncol, 18, pp. 273-279, (2000)

[6]

Cote R.J., Lerner S.P., Datar R., Vogelzang N.J., Scardino P.T., Shipley W.U., Et al., Molecular biology and prognostic markers in bladder cancer, Comprehensive Textbook of Genitourinary Oncology 3rd Edn., pp. 385-401, (2005)

[7]

Wu X.-R., Urothelial tumorigenesis: A tale of divergent pathways, Nat Rev Cancer, 5, pp. 713-725, (2005)

[8]

Wolff E.M., Liang G., Jones P.A., Mechanism of disease: Genetic and epigenetic alterations that drive bladder cancer, Nat Clin Prac Urol, 2, pp. 502-510, (2005)

[9]

Cappellen D., De Oliveira C., Ricol D., Et al., Frequent activating mutations of FGFR3 in human bladder cancer and cervix carcinomas, Nat Genet, 23, pp. 18-20, (1999)

[10]

Billerey C., Chopin D., Aubriton-Lorton M.H., Et al., Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors, Am J Pathol, 158, pp. 1955-1959, (2001)

← 1 2 3 4 5 6 7 8 9 10 →